JP2011521903A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011521903A5 JP2011521903A5 JP2011506435A JP2011506435A JP2011521903A5 JP 2011521903 A5 JP2011521903 A5 JP 2011521903A5 JP 2011506435 A JP2011506435 A JP 2011506435A JP 2011506435 A JP2011506435 A JP 2011506435A JP 2011521903 A5 JP2011521903 A5 JP 2011521903A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- alkyl
- virus
- acceptable salt
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 49
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 claims description 40
- 150000003839 salts Chemical class 0.000 claims description 28
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims description 24
- 239000003112 inhibitor Substances 0.000 claims description 15
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 claims description 14
- 229910052736 halogen Inorganic materials 0.000 claims description 14
- 150000002367 halogens Chemical class 0.000 claims description 14
- 239000003814 drug Substances 0.000 claims description 13
- 125000004649 C2-C8 alkynyl group Chemical group 0.000 claims description 12
- 241000700605 Viruses Species 0.000 claims description 10
- 229910052717 sulfur Inorganic materials 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 9
- 230000009385 viral infection Effects 0.000 claims description 9
- 208000036142 Viral infection Diseases 0.000 claims description 8
- 125000005884 carbocyclylalkyl group Chemical group 0.000 claims description 8
- 229910052799 carbon Inorganic materials 0.000 claims description 8
- 125000000623 heterocyclic group Chemical group 0.000 claims description 8
- 229910052760 oxygen Inorganic materials 0.000 claims description 8
- 229940124597 therapeutic agent Drugs 0.000 claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 claims description 6
- 125000003118 aryl group Chemical group 0.000 claims description 6
- 150000001721 carbon Chemical group 0.000 claims description 6
- 125000004432 carbon atom Chemical group C* 0.000 claims description 6
- 125000001072 heteroaryl group Chemical group 0.000 claims description 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 6
- 125000000547 substituted alkyl group Chemical group 0.000 claims description 6
- 125000004426 substituted alkynyl group Chemical group 0.000 claims description 6
- 125000003107 substituted aryl group Chemical group 0.000 claims description 6
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims description 6
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 claims description 5
- 101001023866 Arabidopsis thaliana Mannosyl-oligosaccharide glucosidase GCS1 Proteins 0.000 claims description 4
- 241000710780 Bovine viral diarrhea virus 1 Species 0.000 claims description 4
- 241000725619 Dengue virus Species 0.000 claims description 4
- 241000710781 Flaviviridae Species 0.000 claims description 4
- 241000711549 Hepacivirus C Species 0.000 claims description 4
- 102000014150 Interferons Human genes 0.000 claims description 4
- 108010050904 Interferons Proteins 0.000 claims description 4
- 241000710842 Japanese encephalitis virus Species 0.000 claims description 4
- 241000710912 Kunjin virus Species 0.000 claims description 4
- 241000124008 Mammalia Species 0.000 claims description 4
- 241000710908 Murray Valley encephalitis virus Species 0.000 claims description 4
- 241000725177 Omsk hemorrhagic fever virus Species 0.000 claims description 4
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical class N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 claims description 4
- 101800001838 Serine protease/helicase NS3 Proteins 0.000 claims description 4
- 241000710888 St. Louis encephalitis virus Species 0.000 claims description 4
- 241000710771 Tick-borne encephalitis virus Species 0.000 claims description 4
- 241000710886 West Nile virus Species 0.000 claims description 4
- 241000710772 Yellow fever virus Species 0.000 claims description 4
- 241000907316 Zika virus Species 0.000 claims description 4
- 125000000217 alkyl group Chemical group 0.000 claims description 4
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 4
- 239000000134 cyclophilin inhibitor Substances 0.000 claims description 4
- 239000002777 nucleoside Substances 0.000 claims description 4
- 150000003833 nucleoside derivatives Chemical class 0.000 claims description 4
- 239000000137 peptide hydrolase inhibitor Substances 0.000 claims description 4
- 125000005017 substituted alkenyl group Chemical group 0.000 claims description 4
- 229940051021 yellow-fever virus Drugs 0.000 claims description 4
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 claims description 3
- 229940079593 drug Drugs 0.000 claims description 3
- 229910052757 nitrogen Inorganic materials 0.000 claims description 3
- -1 —C (═O) OR 11 Chemical compound 0.000 claims description 3
- 125000003341 7 membered heterocyclic group Chemical group 0.000 claims description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 2
- 208000005176 Hepatitis C Diseases 0.000 claims description 2
- 125000003342 alkenyl group Chemical group 0.000 claims description 2
- 125000000304 alkynyl group Chemical group 0.000 claims description 2
- 229910052794 bromium Inorganic materials 0.000 claims description 2
- 125000002837 carbocyclic group Chemical group 0.000 claims description 2
- 229910052801 chlorine Inorganic materials 0.000 claims description 2
- 125000004122 cyclic group Chemical group 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 229910052731 fluorine Inorganic materials 0.000 claims description 2
- 125000001475 halogen functional group Chemical group 0.000 claims description 2
- 229910052739 hydrogen Inorganic materials 0.000 claims description 2
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims description 2
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims description 2
- 230000002401 inhibitory effect Effects 0.000 claims description 2
- 229940079322 interferon Drugs 0.000 claims description 2
- 229940047124 interferons Drugs 0.000 claims description 2
- 229910052740 iodine Inorganic materials 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 9
- 108060004795 Methyltransferase Proteins 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 229940122806 Cyclophilin inhibitor Drugs 0.000 description 1
- 208000004576 Flaviviridae Infections Diseases 0.000 description 1
- FWKQNCXZGNBPFD-UHFFFAOYSA-N Guaiazulene Chemical compound CC(C)C1=CC=C(C)C2=CC=C(C)C2=C1 FWKQNCXZGNBPFD-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229940123066 Polymerase inhibitor Drugs 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US4726308P | 2008-04-23 | 2008-04-23 | |
| US61/047,263 | 2008-04-23 | ||
| US13944908P | 2008-12-19 | 2008-12-19 | |
| US61/139,449 | 2008-12-19 | ||
| PCT/US2009/041447 WO2009132135A1 (en) | 2008-04-23 | 2009-04-22 | 1' -substituted carba-nucleoside analogs for antiviral treatment |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013218129A Division JP2014040471A (ja) | 2008-04-23 | 2013-10-21 | 抗ウイルス処置のための１’−置換カルバ−ヌクレオシドアナログ |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011521903A JP2011521903A (ja) | 2011-07-28 |
| JP2011521903A5 true JP2011521903A5 (enExample) | 2013-04-04 |
| JP5425187B2 JP5425187B2 (ja) | 2014-02-26 |
Family
ID=40887058
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011506429A Active JP5425186B2 (ja) | 2008-04-23 | 2009-04-22 | 抗ウイルス処置のためのカルバ−ヌクレオシドアナログ |
| JP2011506435A Active JP5425187B2 (ja) | 2008-04-23 | 2009-04-22 | 抗ウイルス処置のための１’−置換カルバ−ヌクレオシドアナログ |
| JP2013218129A Withdrawn JP2014040471A (ja) | 2008-04-23 | 2013-10-21 | 抗ウイルス処置のための１’−置換カルバ−ヌクレオシドアナログ |
| JP2013218139A Withdrawn JP2014012739A (ja) | 2008-04-23 | 2013-10-21 | 抗ウイルス処置のためのカルバ−ヌクレオシドアナログ |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011506429A Active JP5425186B2 (ja) | 2008-04-23 | 2009-04-22 | 抗ウイルス処置のためのカルバ−ヌクレオシドアナログ |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013218129A Withdrawn JP2014040471A (ja) | 2008-04-23 | 2013-10-21 | 抗ウイルス処置のための１’−置換カルバ−ヌクレオシドアナログ |
| JP2013218139A Withdrawn JP2014012739A (ja) | 2008-04-23 | 2013-10-21 | 抗ウイルス処置のためのカルバ−ヌクレオシドアナログ |
Country Status (32)
Families Citing this family (186)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY164523A (en) | 2000-05-23 | 2017-12-29 | Univ Degli Studi Cagliari | Methods and compositions for treating hepatitis c virus |
| AU2001272923A1 (en) | 2000-05-26 | 2001-12-11 | Idenix (Cayman) Limited | Methods and compositions for treating flaviviruses and pestiviruses |
| CN1849142A (zh) | 2002-11-15 | 2006-10-18 | 埃迪尼克斯(开曼)有限公司 | 2′－支链核苷和黄病毒突变 |
| CN102046626A (zh) * | 2008-04-23 | 2011-05-04 | 吉里德科学公司 | 用于抗病毒治疗的carba-核苷类似物 |
| US8173621B2 (en) | 2008-06-11 | 2012-05-08 | Gilead Pharmasset Llc | Nucleoside cyclicphosphates |
| EP2313102A2 (en) | 2008-07-03 | 2011-04-27 | Biota Scientific Management | Bycyclic nucleosides and nucleotides as therapeutic agents |
| EA026557B1 (ru) | 2008-12-09 | 2017-04-28 | Джилид Сайэнс, Инк. | Промежуточные соединения для получения модуляторов толл-подобных рецепторов |
| MX2011006891A (es) | 2008-12-23 | 2011-10-06 | Pharmasset Inc | Fosforamidatos de nucleosidos. |
| US8716263B2 (en) | 2008-12-23 | 2014-05-06 | Gilead Pharmasset Llc | Synthesis of purine nucleosides |
| CN102753563A (zh) | 2008-12-23 | 2012-10-24 | 吉利德制药有限责任公司 | 核苷类似物 |
| TWI583692B (zh) | 2009-05-20 | 2017-05-21 | 基利法瑪席特有限責任公司 | 核苷磷醯胺 |
| US8618076B2 (en) | 2009-05-20 | 2013-12-31 | Gilead Pharmasset Llc | Nucleoside phosphoramidates |
| US8455451B2 (en) * | 2009-09-21 | 2013-06-04 | Gilead Sciences, Inc. | 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment |
| US7973013B2 (en) | 2009-09-21 | 2011-07-05 | Gilead Sciences, Inc. | 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment |
| DK2480559T3 (da) | 2009-09-21 | 2013-08-05 | Gilead Sciences Inc | Fremgangsmåder og mellemprodukter til fremstillingen af 1'-cyano-carbanukleosid-analoger |
| KR20180006499A (ko) * | 2009-09-21 | 2018-01-17 | 길리애드 사이언시즈, 인코포레이티드 | 항바이러스 치료용 ２'―플루오로 치환된 카바-뉴클레오사이드 유사체 |
| AU2010311511B2 (en) | 2009-10-30 | 2014-07-17 | Janssen Pharmaceutica Nv | Imidazo[1,2-b]pyridazine derivatives and their use as PDE10 inhibitors |
| AR080754A1 (es) | 2010-03-09 | 2012-05-09 | Janssen Pharmaceutica Nv | Derivados de imidazo (1,2-a) pirazina y su uso como inhibidores de pde10 |
| EA026341B9 (ru) * | 2010-03-31 | 2021-12-27 | ГАЙЛИД ФАРМАССЕТ ЭлЭлСи | Кристаллическая форма нуклеозидфосфорамидата |
| TW201201815A (en) * | 2010-05-28 | 2012-01-16 | Gilead Sciences Inc | 1'-substituted-carba-nucleoside prodrugs for antiviral treatment |
| PH12013500033A1 (en) | 2010-07-19 | 2017-07-26 | Gilead Sciences Inc | Methods for the preparation of diasteromerically pure phosphoramidate prodrugs |
| MA34470B1 (fr) * | 2010-07-22 | 2013-08-01 | Gilead Sciences Inc | Procédés et composés pour traiter des infections à virus paramyxoviridae |
| TW201305185A (zh) * | 2010-09-13 | 2013-02-01 | Gilead Sciences Inc | 用於抗病毒治療之２’－氟取代之碳－核苷類似物 |
| AU2011306066B2 (en) * | 2010-09-20 | 2015-01-29 | Gilead Sciences, Inc. | 2' -fluoro substituted carba-nucleoside analogs for antiviral treatment |
| AU2011305652B2 (en) | 2010-09-22 | 2016-10-20 | Janssen Biopharma, Inc. | Azido nucleosides and nucleotide analogs |
| US8841275B2 (en) | 2010-11-30 | 2014-09-23 | Gilead Pharmasset Llc | 2′-spiro-nucleosides and derivatives thereof useful for treating hepatitis C virus and dengue virus infections |
| TW201306841A (zh) * | 2010-12-20 | 2013-02-16 | Gilead Sciences Inc | 治療ｃ型肝炎病毒（ｈｃｖ）之方法 |
| CA2843324A1 (en) | 2011-03-31 | 2012-11-15 | Idenix Pharmaceuticals, Inc. | Compounds and pharmaceutical compositions for the treatment of viral infections |
| US8877744B2 (en) * | 2011-04-04 | 2014-11-04 | Hoffmann-La Roche Inc. | 1,4-Oxazepines as BACE1 and/or BACE2 inhibitors |
| EA201391519A1 (ru) * | 2011-04-13 | 2014-03-31 | Мерк Шарп И Доум Корп. | 2'-замещенные нуклеозидные производные и способы их применения для лечения вирусных заболеваний |
| WO2012142075A1 (en) * | 2011-04-13 | 2012-10-18 | Merck Sharp & Dohme Corp. | 2'-azido substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases |
| WO2012142093A2 (en) * | 2011-04-13 | 2012-10-18 | Merck Sharp & Dohme Corp. | 2'-cyano substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases |
| CN103619846B (zh) | 2011-06-27 | 2016-08-17 | 詹森药业有限公司 | 1-芳基-4-甲基-[1,2,4]三唑[4,3-a]喹喔啉衍生物 |
| EP2731433A4 (en) | 2011-07-13 | 2014-12-31 | Merck Sharp & Dohme | 5'-SUBSTITUTED NUCLEOSIDE ANALOGA AND METHOD FOR THEIR USE FOR THE TREATMENT OF VIRUS DISEASES |
| WO2013009735A1 (en) | 2011-07-13 | 2013-01-17 | Merck Sharp & Dohme Corp. | 5'-substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases |
| WO2013030750A1 (en) | 2011-09-01 | 2013-03-07 | Lupin Limited | Antiviral compounds |
| TW201329096A (zh) | 2011-09-12 | 2013-07-16 | Idenix Pharmaceuticals Inc | 經取代羰氧基甲基磷酸醯胺化合物及用於治療病毒感染之藥學組成物 |
| EP2709613B2 (en) | 2011-09-16 | 2020-08-12 | Gilead Pharmasset LLC | Methods for treating hcv |
| WO2013049352A2 (en) * | 2011-09-30 | 2013-04-04 | Kineta, Inc. | Anti-viral compounds |
| WO2013056046A1 (en) | 2011-10-14 | 2013-04-18 | Idenix Pharmaceuticals, Inc. | Substituted 3',5'-cyclic phosphates of purine nucleotide compounds and pharmaceutical compositions for the treatment of viral infections |
| SG2014011670A (en) * | 2011-10-21 | 2014-10-30 | Abbvie Inc | Combination treatment (eg. with abt-072 or abt -333) of daas for use in treating hcv |
| US8889159B2 (en) | 2011-11-29 | 2014-11-18 | Gilead Pharmasset Llc | Compositions and methods for treating hepatitis C virus |
| CA2862755A1 (en) | 2012-02-10 | 2013-08-15 | Lupin Limited | Antiviral compounds with a dibenzooxaheterocycle moiety |
| JP6242378B2 (ja) | 2012-03-13 | 2017-12-06 | ギリアード サイエンシーズ， インコーポレイテッド | 抗ウイルス処置のための２’−置換カルバヌクレオシド類似体 |
| CN104470939B (zh) | 2012-05-22 | 2017-04-26 | 埃迪尼克斯医药有限责任公司 | 用于肝脏疾病的d型氨基酸化合物 |
| US9296778B2 (en) * | 2012-05-22 | 2016-03-29 | Idenix Pharmaceuticals, Inc. | 3′,5′-cyclic phosphate prodrugs for HCV infection |
| EP2852604B1 (en) | 2012-05-22 | 2017-04-12 | Idenix Pharmaceuticals LLC | 3',5'-cyclic phosphoramidate prodrugs for hcv infection |
| PL2861611T3 (pl) | 2012-05-25 | 2017-08-31 | Janssen Sciences Ireland Uc | Nukleozydy uracylowe spirooksetanu |
| EP2863909B1 (en) | 2012-06-26 | 2020-11-04 | Janssen Pharmaceutica N.V. | Combinations comprising 4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline compounds as pde 2 inhibitors and pde 10 inhibitors for use in the treatment of neurological or metabolic disorders |
| ES2607184T3 (es) | 2012-07-09 | 2017-03-29 | Janssen Pharmaceutica, N.V. | Inhibidores de la enzima fosfodiesterasa 10 |
| WO2014035140A2 (en) * | 2012-08-30 | 2014-03-06 | Kainos Medicine, Inc. | Compounds and compositions for modulating histone methyltransferase activity |
| WO2014042433A2 (en) * | 2012-09-14 | 2014-03-20 | Kainos Medicine, Inc. | Compounds and compositions for modulating adenosine a3 receptor activity |
| WO2014052638A1 (en) * | 2012-09-27 | 2014-04-03 | Idenix Pharmaceuticals, Inc. | Esters and malonates of sate prodrugs |
| HK1207647A1 (en) | 2012-10-08 | 2016-02-05 | Idenix Pharmaceuticals Llc | 2'-chloro nucleoside analogs for hcv infection |
| WO2014059902A1 (en) * | 2012-10-17 | 2014-04-24 | Merck Sharp & Dohme Corp. | 2'-disubstituted substituted nucleoside derivatives and methods of use thereof for treatment of viral diseases |
| WO2014059901A1 (en) | 2012-10-17 | 2014-04-24 | Merck Sharp & Dohme Corp. | 2'-cyano substituted nucleoside derivatives and methods of use thereof for treatment of viral diseases |
| AR092959A1 (es) | 2012-10-17 | 2015-05-06 | Merck Sharp & Dohme | Derivados de nucleosidos 2-metil sustituidos y metodos de uso de los mismos para el tratamiento de enfermedades virales |
| WO2014066239A1 (en) | 2012-10-22 | 2014-05-01 | Idenix Pharmaceuticals, Inc. | 2',4'-bridged nucleosides for hcv infection |
| RU2015123641A (ru) | 2012-11-19 | 2017-01-10 | Мерк Шарп И Доум Корп. | 2-алкинилзамещенные производные нуклеозидов, предназначенные для лечения вирусных заболеваний |
| EP2935304A1 (en) | 2012-12-19 | 2015-10-28 | IDENIX Pharmaceuticals, Inc. | 4'-fluoro nucleosides for the treatment of hcv |
| UA118256C2 (uk) | 2013-01-31 | 2018-12-26 | Гіліад Фармассет Елелсі | Комбінований склад двох противірусних сполук |
| US10034893B2 (en) | 2013-02-01 | 2018-07-31 | Enanta Pharmaceuticals, Inc. | 5, 6-D2 uridine nucleoside/tide derivatives |
| WO2014137926A1 (en) | 2013-03-04 | 2014-09-12 | Idenix Pharmaceuticals, Inc. | 3'-deoxy nucleosides for the treatment of hcv |
| WO2014137930A1 (en) | 2013-03-04 | 2014-09-12 | Idenix Pharmaceuticals, Inc. | Thiophosphate nucleosides for the treatment of hcv |
| EP2970357B1 (en) | 2013-03-13 | 2025-01-01 | Idenix Pharmaceuticals LLC | Amino acid phosphoramidate pronucleotides of 2'-cyano, azido and amino nucleosides for the treatment of hcv |
| WO2014165542A1 (en) | 2013-04-01 | 2014-10-09 | Idenix Pharmaceuticals, Inc. | 2',4'-fluoro nucleosides for the treatment of hcv |
| US10005779B2 (en) | 2013-06-05 | 2018-06-26 | Idenix Pharmaceuticals Llc | 1′,4′-thio nucleosides for the treatment of HCV |
| EP3010512B1 (en) | 2013-06-18 | 2017-12-27 | Merck Sharp & Dohme Corp. | Cyclic phosphonate substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases |
| WO2015017713A1 (en) | 2013-08-01 | 2015-02-05 | Idenix Pharmaceuticals, Inc. | D-amino acid phosphoramidate pronucleotides of halogeno pyrimidine compounds for liver disease |
| UA119050C2 (uk) | 2013-11-11 | 2019-04-25 | Ґілеад Саєнсиз, Інк. | ПІРОЛО[1.2-f][1.2.4]ТРИАЗИНИ, ЯКІ ВИКОРИСТОВУЮТЬСЯ ДЛЯ ЛІКУВАННЯ РЕСПІРАТОРНО-СИНЦИТІАЛЬНИХ ВІРУСНИХ ІНФЕКЦІЙ |
| EP3074399A1 (en) * | 2013-11-27 | 2016-10-05 | Idenix Pharmaceuticals LLC | 2'-dichloro and 2'-fluoro-2'-chloro nucleoside analogues for hcv infection |
| WO2015143712A1 (en) | 2014-03-28 | 2015-10-01 | Merck Sharp & Dohme Corp. | 4'-substituted nucleoside reverse transcriptase inhibitors |
| WO2015161137A1 (en) | 2014-04-16 | 2015-10-22 | Idenix Pharmaceuticals, Inc. | 3'-substituted methyl or alkynyl nucleosides for the treatment of hcv |
| WO2015166370A1 (en) | 2014-04-28 | 2015-11-05 | Pfizer Inc. | Heteroaromatic compounds and their use as dopamine d1 ligands |
| PT3166607T (pt) | 2014-07-11 | 2022-12-07 | Gilead Sciences Inc | Moduladores de receptores de tipo toll para o tratamento do vih |
| TWI678369B (zh) * | 2014-07-28 | 2019-12-01 | 美商基利科學股份有限公司 | 用於治療呼吸道合胞病毒感染之噻吩並［３,２-ｄ］嘧啶、呋喃並［３,２-ｄ］嘧啶及吡咯並［３,２-ｄ］嘧啶化合物類 |
| WO2016023522A2 (en) | 2014-08-15 | 2016-02-18 | Merck Sharp & Dohme Corp. | Substituted phosphoramidate compounds and uses thereof |
| TWI673283B (zh) | 2014-08-21 | 2019-10-01 | 美商基利科學股份有限公司 | ２’－氯胺基嘧啶酮及嘧啶二酮核苷類 |
| US9675632B2 (en) | 2014-08-26 | 2017-06-13 | Enanta Pharmaceuticals, Inc. | Nucleoside and nucleotide derivatives |
| AU2015318061B2 (en) | 2014-09-16 | 2018-05-17 | Gilead Sciences, Inc. | Solid forms of a toll-like receptor modulator |
| TWI767201B (zh) | 2014-10-29 | 2022-06-11 | 美商基利科學股份有限公司 | 絲狀病毒科病毒感染之治療 |
| US20170334941A1 (en) * | 2014-10-31 | 2017-11-23 | Cocrystal Pharma, Inc. | 2',2'-dihalo nucleoside analogs for treatment of the flaviviridae family of viruses and cancer |
| US9718851B2 (en) | 2014-11-06 | 2017-08-01 | Enanta Pharmaceuticals, Inc. | Deuterated nucleoside/tide derivatives |
| US9732110B2 (en) | 2014-12-05 | 2017-08-15 | Enanta Pharmaceuticals, Inc. | Nucleoside and nucleotide derivatives |
| EP3233878B1 (en) | 2014-12-15 | 2025-09-03 | Emory University | Phosphoramidates for the treatment of hepatitis b virus |
| CN118286245A (zh) | 2014-12-26 | 2024-07-05 | 埃莫里大学 | N4-羟基胞苷和衍生物及与其相关的抗病毒用途 |
| EA039561B1 (ru) * | 2015-01-20 | 2022-02-10 | Джилид Сайэнс, Инк. | Соединения для лечения вирусных инфекций filoviridae |
| CN107427530B (zh) | 2015-03-06 | 2020-09-08 | 阿堤亚制药公司 | 用于HCV治疗的β-D-2’-脱氧-2’α-氟-2’-β-C-取代的-2-改性的-N6-取代的嘌呤核苷酸 |
| WO2016160646A1 (en) | 2015-04-02 | 2016-10-06 | Merck Sharp & Dohme Corp. | Process for making phosphoramidate protected nucleoside compounds |
| WO2016178876A2 (en) | 2015-05-01 | 2016-11-10 | Cocrystal Pharma, Inc. | Nucleoside analogs for treatment of the flaviviridae family of viruses and cancer |
| CN107592864B (zh) * | 2015-05-12 | 2021-04-16 | 豪夫迈·罗氏有限公司 | 用于治疗和预防病毒感染的新的取代的氨基噻唑并嘧啶二酮 |
| EA035664B1 (ru) | 2015-08-05 | 2020-07-23 | МЕТРО ИНТЕРНЭШНЛ БАЙОТЕК, ЭлЭлСи | Производные никотинамидмононуклеотида и их применение для лечения заболевания или расстройства, связанного с биосинтезом над+ |
| MX394858B (es) | 2015-09-16 | 2025-03-24 | Gilead Sciences Inc | Compuestos de formula i para usarse en el tratamiento de infecciones por virus arenaviridae y coronaviridae |
| RU2720811C2 (ru) | 2015-09-23 | 2020-05-13 | Мерк Шарп И Доум Лимитед | 4'-замещенные нуклеозидные ингибиторы обратной транскриптазы и их получение |
| AU2017231824B2 (en) | 2016-03-09 | 2021-07-01 | Alios Biopharma, Inc. | Acyclic antivirals |
| PT3436461T (pt) | 2016-03-28 | 2024-01-23 | Incyte Corp | Compostos de pirrolotriazina como inibidores de tam |
| WO2017184668A1 (en) | 2016-04-20 | 2017-10-26 | Gilead Sciences, Inc. | Methods for treating flaviviridae virus infections |
| WO2017184670A2 (en) | 2016-04-22 | 2017-10-26 | Gilead Sciences, Inc. | Methods for treating zika virus infections |
| EA201990059A1 (ru) | 2016-06-24 | 2019-07-31 | Эмори Юниверсити | Фосфорамидаты для лечения вируса гепатита b |
| US10202412B2 (en) | 2016-07-08 | 2019-02-12 | Atea Pharmaceuticals, Inc. | β-D-2′-deoxy-2′-substituted-4′-substituted-2-substituted-N6-substituted-6-aminopurinenucleotides for the treatment of paramyxovirus and orthomyxovirus infections |
| WO2018013937A1 (en) | 2016-07-14 | 2018-01-18 | Atea Pharmaceuticals, Inc. | Beta-d-2'-deoxy-2'-alpha-fluoro-2'-beta-c-substituted-4'-fluoro-n6-substituted-6-amino-2-substituted purine nucleotides for the treatment of hepatitis c virus infection |
| WO2018031818A2 (en) * | 2016-08-12 | 2018-02-15 | Alios Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
| AU2017324939B2 (en) | 2016-09-07 | 2021-10-14 | Atea Pharmaceuticals, Inc. | 2'-substituted-N6-substituted purine nucleotides for RNA virus treatment |
| US20190350960A1 (en) | 2017-01-04 | 2019-11-21 | President And Fellows Of Harvard College | Modulating nudix homology domain (nhd) with nicotinamide mononucleotide analogs and derivatives of same |
| US10519186B2 (en) | 2017-02-01 | 2019-12-31 | Atea Pharmaceuticals, Inc. | Nucleotide hemi-sulfate salt for the treatment of hepatitis C virus |
| CA3056072C (en) | 2017-03-14 | 2022-08-23 | Gilead Sciences, Inc. | Methods of treating feline coronavirus infections |
| KR20190141747A (ko) | 2017-05-01 | 2019-12-24 | 길리애드 사이언시즈, 인코포레이티드 | (S)-2-에틸부틸 2-(((S)-(((2R,3S,4R,5R)-5-(4-아미노피롤로[2,1-f] [1,2,4]트리아진-7-일)-5-시아노-3,4-디히드록시테트라히드로푸란-2-일)메톡시)(페녹시) 포스포릴)아미노)프로파노에이트의 결정질 형태 |
| EP4512475A3 (en) | 2017-07-11 | 2025-05-14 | Gilead Sciences, Inc. | Compositions comprising an rna polymerase inhibitor and cyclodextrin for treating viral infections |
| TWI624264B (zh) * | 2017-08-11 | 2018-05-21 | 景鑫生物科技股份有限公司 | 南洋山蘇水萃物的用途 |
| AU2018332540B2 (en) | 2017-09-18 | 2023-10-05 | Janssen Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
| RS66222B1 (sr) | 2017-12-07 | 2024-12-31 | Univ Emory | N4-hidroksicitidin i derivati i antivirusne upotrebe povezane sa njim |
| US11040975B2 (en) | 2017-12-08 | 2021-06-22 | Merck Sharp & Dohme Corp. | Carbocyclic nucleoside reverse transcriptase inhibitors |
| WO2019133712A1 (en) * | 2017-12-27 | 2019-07-04 | Schinazi Raymond F | Combined modalities for nucleosides and/or nadph oxidase (nox) inhibitors as myeloid-specific antiviral agents |
| KR20200140865A (ko) | 2018-04-10 | 2020-12-16 | 아테아 파마슈티컬즈, 인크. | 간경변증을 갖는 hcv 감염 환자의 치료 |
| HUE059677T2 (hu) | 2019-03-22 | 2022-12-28 | Gilead Sciences Inc | Áthidalt triciklusos karbamoilpiridon-vegyületek és ezek gyógyszerészeti alkalmazása |
| JP7621974B2 (ja) | 2019-05-09 | 2025-01-27 | アリゴス セラピューティクス インコーポレイテッド | Ｓｔｉｎｇモジュレータとしての修飾環状ジヌクレオシド化合物 |
| CN112321590A (zh) * | 2019-08-02 | 2021-02-05 | 百济神州有限公司 | 咪唑并[2,1-f][1,2,4]三嗪-4-胺衍生物作为tlr8激动剂 |
| CN110724174B (zh) * | 2019-09-10 | 2021-02-05 | 广州六顺生物科技股份有限公司 | 吡咯并三嗪类化合物、组合物及其应用 |
| AU2021214911A1 (en) | 2020-01-27 | 2022-07-21 | Gilead Sciences, Inc. | Methods for treating SARS CoV-2 infections |
| CN113214334A (zh) * | 2020-02-05 | 2021-08-06 | 华创合成制药股份有限公司 | 用于治疗病毒感染的化合物及其制备方法和用途 |
| CN113214262B (zh) * | 2020-02-05 | 2023-07-07 | 华创合成制药股份有限公司 | 一种含有胍基的化合物及其制备方法和用途 |
| TWI791193B (zh) | 2020-02-18 | 2023-02-01 | 美商基利科學股份有限公司 | 抗病毒化合物 |
| TWI775313B (zh) | 2020-02-18 | 2022-08-21 | 美商基利科學股份有限公司 | 抗病毒化合物 |
| TWI883391B (zh) | 2020-02-18 | 2025-05-11 | 美商基利科學股份有限公司 | 抗病毒化合物 |
| AU2021224588B2 (en) | 2020-02-18 | 2024-07-18 | Gilead Sciences, Inc. | Antiviral compounds |
| CN113292565B (zh) * | 2020-02-24 | 2023-01-31 | 浙江森科建设有限公司 | 核苷类化合物及其制备方法和应用 |
| US10874687B1 (en) | 2020-02-27 | 2020-12-29 | Atea Pharmaceuticals, Inc. | Highly active compounds against COVID-19 |
| CN111269248A (zh) * | 2020-03-05 | 2020-06-12 | 江苏福瑞康泰药业有限公司 | 一种核苷氨基磷酸酯类药物母液回收的新方法 |
| KR20220153619A (ko) | 2020-03-12 | 2022-11-18 | 길리애드 사이언시즈, 인코포레이티드 | 1'-시아노 뉴클레오사이드의 제조 방법 |
| WO2021188959A1 (en) | 2020-03-20 | 2021-09-23 | Gilead Sciences, Inc. | Prodrugs of 4'-c-substituted-2-halo-2'-deoxyadenosine nucleosides and methods of making and using the same |
| EP4125810A1 (en) | 2020-03-22 | 2023-02-08 | InspirMed Corp. | Composition of antiviral agent for use in prophylactic or post-exposure treatment of infectious or respiratory diseases |
| WO2021202669A2 (en) | 2020-04-01 | 2021-10-07 | Reyoung Corporation | Nucleoside and nucleotide conjugate compounds and uses thereof |
| WO2021207049A1 (en) | 2020-04-06 | 2021-10-14 | Gilead Sciences, Inc. | Inhalation formulations of 1'-cyano substituted carbanucleoside analogs |
| CN112778310B (zh) * | 2020-04-20 | 2025-05-30 | 中国科学院上海药物研究所 | 核苷类似物或含有核苷类似物的组合制剂在抗病毒中的应用 |
| WO2021216427A1 (en) * | 2020-04-21 | 2021-10-28 | Ligand Pharmaceuticals, Inc. | Nucleotide prodrug compounds |
| JP7664287B2 (ja) | 2020-05-29 | 2025-04-17 | ギリアード サイエンシーズ， インコーポレイテッド | レムデシビル治療方法 |
| AU2021296841B2 (en) | 2020-06-24 | 2025-01-23 | Gilead Sciences, Inc. | 1'-cyano nucleoside analogs and uses thereof |
| EP4185283A4 (en) * | 2020-07-23 | 2024-08-07 | Arjil Biotech Holding Company Limited | METHOD AND COMPOSITION FOR INHIBITING VIRAL INFECTION |
| LT4192839T (lt) | 2020-08-06 | 2025-11-25 | Remdesiviro tarpiniai junginiai | |
| CN111956630A (zh) * | 2020-08-20 | 2020-11-20 | 大连理工大学 | 一种瑞德西韦供雾化器用的液体制剂、制备方法及其应用 |
| JP7559223B2 (ja) | 2020-08-24 | 2024-10-01 | ギリアード サイエンシーズ， インコーポレイテッド | リン脂質化合物及びその使用 |
| KR20250111239A (ko) | 2020-08-27 | 2025-07-22 | 길리애드 사이언시즈, 인코포레이티드 | 바이러스 감염 치료를 위한 화합물 및 방법 |
| CN114149434A (zh) * | 2020-09-08 | 2022-03-08 | 安徽诺全药业有限公司 | 一种杂环化合物及其制备方法、应用 |
| TW202344257A (zh) * | 2020-10-16 | 2023-11-16 | 美商基利科學股份有限公司 | 磷脂化合物及其用途 |
| TWI815194B (zh) | 2020-10-22 | 2023-09-11 | 美商基利科學股份有限公司 | 介白素2-Fc融合蛋白及使用方法 |
| US12274700B1 (en) | 2020-10-30 | 2025-04-15 | Accencio LLC | Methods of treating symptoms of coronavirus infection with RNA polymerase inhibitors |
| WO2022098371A1 (en) * | 2020-11-09 | 2022-05-12 | Yan Matthew | Prodrugs of 1'-substituted carba-nucleoside analogues for antiviral treatment |
| CA3195799A1 (en) | 2020-11-11 | 2022-05-19 | Stephen R. Martin | Methods of identifying hiv patients sensitive to therapy with gp120 cd4 binding site-directed antibodies |
| CN112494500B (zh) * | 2020-11-26 | 2022-01-11 | 北京箭牧科技有限公司 | 瑞德西韦在制备治疗抗肿瘤药物心脏毒性药物中的应用 |
| CN114621229B (zh) * | 2020-12-11 | 2024-07-02 | 嘉兴金派特生物科技有限公司 | 治疗或预防猫传染性腹膜炎的化合物或组合物 |
| CN112592348B (zh) * | 2020-12-21 | 2022-03-08 | 南京法恩化学有限公司 | 一种4-氨基吡咯并[2,1-f][1,2,4]三嗪的制备方法 |
| CN118027040A (zh) * | 2020-12-30 | 2024-05-14 | 南方科技大学 | 一种治疗冠状病毒感染的核苷类化合物及其用途 |
| KR20230170745A (ko) | 2021-04-16 | 2023-12-19 | 길리애드 사이언시즈, 인코포레이티드 | 아미드를 사용한 카르바뉴클레오시드를 제조하는 방법 |
| CN117500494A (zh) | 2021-06-17 | 2024-02-02 | 阿堤亚制药公司 | 有利的抗hcv联合疗法 |
| KR20230001208A (ko) | 2021-06-28 | 2023-01-04 | 동아대학교 산학협력단 | 오각고리 염기를 포함하는 비고리형 핵산 모방체 |
| CN115703796A (zh) * | 2021-08-09 | 2023-02-17 | 苏州恩泰新材料科技有限公司 | 一种瑞德西韦重要中间体制备方法 |
| US12116380B2 (en) | 2021-08-18 | 2024-10-15 | Gilead Sciences, Inc. | Phospholipid compounds and methods of making and using the same |
| EP4440702B1 (en) | 2021-12-03 | 2025-05-21 | Gilead Sciences, Inc. | Therapeutic compounds for hiv virus infection |
| JP7736929B2 (ja) | 2021-12-03 | 2025-09-09 | ギリアード サイエンシーズ， インコーポレイテッド | Ｈｉｖウイルス感染症のための治療化合物 |
| US12084467B2 (en) | 2021-12-03 | 2024-09-10 | Gilead Sciences, Inc. | Therapeutic compounds for HIV virus infection |
| CA3244278A1 (en) | 2022-03-02 | 2023-09-07 | Gilead Sciences Inc | COMPOUNDS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS |
| TWI843506B (zh) | 2022-04-06 | 2024-05-21 | 美商基利科學股份有限公司 | 橋聯三環胺甲醯基吡啶酮化合物及其用途 |
| CN114437159B (zh) * | 2022-04-11 | 2022-06-28 | 佛山市晨康生物科技有限公司 | 一种环状碳酸酯核苷类化合物及其应用 |
| AU2023261450A1 (en) * | 2022-04-25 | 2024-11-14 | Miracure Biotechnology Limited | Nucleoside drug for treating or preventing coronavirus infection, and use thereof |
| US20240043466A1 (en) * | 2022-06-30 | 2024-02-08 | Gilead Sciences, Inc. | Solid forms of a nucleoside analogue and uses thereof |
| WO2024006982A1 (en) | 2022-07-01 | 2024-01-04 | Gilead Sciences, Inc. | Therapeutic compounds useful for the prophylactic or therapeutic treatment of an hiv virus infection |
| US20240083984A1 (en) | 2022-08-26 | 2024-03-14 | Gilead Sciences, Inc. | Dosing and scheduling regimen for broadly neutralizing antibodies |
| US20240226130A1 (en) | 2022-10-04 | 2024-07-11 | Gilead Sciences, Inc. | 4'-thionucleoside analogues and their pharmaceutical use |
| EP4605396A1 (en) * | 2022-10-23 | 2025-08-27 | Shanghai Curegene Pharmaceutical Co., Ltd. | Anticoronviral compounds and compositions and uses thereof |
| WO2024088184A1 (en) * | 2022-10-23 | 2024-05-02 | Shanghai Curegene Pharmaceutical Co., Ltd. | Anti-feline-coronavirus compounds and uses thereof |
| CN115819423B (zh) * | 2022-11-29 | 2024-11-22 | 武汉大学 | 一种瑞德西韦或其中间体的protac化合物及其制备方法与抗ev71的应用 |
| AR132464A1 (es) | 2023-04-19 | 2025-07-02 | Gilead Sciences Inc | Régimen de dosificación de inhibidor de la cápside |
| CN116217621B (zh) * | 2023-04-26 | 2023-08-11 | 北京沐华生物科技有限责任公司 | 一种核苷类双前药、合成方法及应用 |
| CN118852168B (zh) * | 2023-04-26 | 2025-09-19 | 深圳科兴药业有限公司 | 一种制备苄基碳核苷类似物的新方法及其应用 |
| WO2024249573A1 (en) | 2023-05-31 | 2024-12-05 | Gilead Sciences, Inc. | Solid forms of compounds useful in the treatment of hiv |
| TW202448483A (zh) | 2023-05-31 | 2024-12-16 | 美商基利科學股份有限公司 | 用於ｈｉｖ之治療性化合物 |
| WO2025029247A1 (en) | 2023-07-28 | 2025-02-06 | Gilead Sciences, Inc. | Weekly regimen of lenacapavir for the treatment and prevention of hiv |
| WO2025042394A1 (en) | 2023-08-23 | 2025-02-27 | Gilead Sciences, Inc. | Dosing regimen of hiv capsid inhibitor |
| TW202530226A (zh) | 2023-10-11 | 2025-08-01 | 美商基利科學股份有限公司 | 橋聯三環胺甲醯基吡啶酮化合物及其用途 |
| TW202515549A (zh) | 2023-10-11 | 2025-04-16 | 美商基利科學股份有限公司 | 橋聯三環胺甲醯基吡啶酮化合物及其用途 |
| WO2025080863A1 (en) | 2023-10-11 | 2025-04-17 | Gilead Sciences, Inc. | Bridged tricyclic carbamoylpyridone compounds and uses thereof |
| WO2025137245A1 (en) | 2023-12-22 | 2025-06-26 | Gilead Sciences, Inc. | Solid forms of hiv integrase inhibitors |
| US12357577B1 (en) | 2024-02-02 | 2025-07-15 | Gilead Sciences, Inc. | Pharmaceutical formulations and uses thereof |
| US20250333424A1 (en) | 2024-03-01 | 2025-10-30 | Gilead Sciences, Inc. | Antiviral compounds |
| WO2025184447A1 (en) | 2024-03-01 | 2025-09-04 | Gilead Sciences, Inc. | Pharmaceutical compositions comprising hiv integrase inhibitors |
| US20250289822A1 (en) | 2024-03-01 | 2025-09-18 | Gilead Sciences, Inc. | Solid forms of hiv integrase inhibitors |
Family Cites Families (77)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816570A (en) * | 1982-11-30 | 1989-03-28 | The Board Of Regents Of The University Of Texas System | Biologically reversible phosphate and phosphonate protective groups |
| JPS59141856A (ja) | 1983-02-02 | 1984-08-14 | Fuji Electric Co Ltd | Ｆｓ変復調方式 |
| US4968788A (en) * | 1986-04-04 | 1990-11-06 | Board Of Regents, The University Of Texas System | Biologically reversible phosphate and phosphonate protective gruops |
| JP3347723B2 (ja) | 1990-06-13 | 2002-11-20 | グラツィエル，アーノルド | 含リンプロドラッグ |
| ES2118069T3 (es) * | 1990-09-14 | 1998-09-16 | Acad Of Science Czech Republic | Profarmacos de fosfonatos. |
| US6887707B2 (en) | 1996-10-28 | 2005-05-03 | University Of Washington | Induction of viral mutation by incorporation of miscoding ribonucleoside analogs into viral RNA |
| US6312662B1 (en) * | 1998-03-06 | 2001-11-06 | Metabasis Therapeutics, Inc. | Prodrugs phosphorus-containing compounds |
| ATE371659T1 (de) | 1998-10-16 | 2007-09-15 | Merck Sharp & Dohme | Pyrazolotriazinderivate als gaba-rezeptorliganden |
| DE19912636A1 (de) | 1999-03-20 | 2000-09-21 | Aventis Cropscience Gmbh | Bicyclische Heterocyclen, Verfahren zu ihrer Herstellung und ihre Verwendung als Herbizide und pharmazeutische Mittel |
| WO2001019375A1 (en) | 1999-09-15 | 2001-03-22 | Biocryst Pharmaceuticals, Inc. | Inhibiting t-cell proliferation |
| CA2389745C (en) | 1999-11-04 | 2010-03-23 | Shire Biochem Inc. | Method for the treatment or prevention of flaviviridae viral infection using nucleoside analogues |
| AU2001235278A1 (en) | 2000-02-18 | 2001-08-27 | Shire Biochem Inc | Method for the treatment or prevention of flavivirus infections using nucleoside analogues |
| MY164523A (en) | 2000-05-23 | 2017-12-29 | Univ Degli Studi Cagliari | Methods and compositions for treating hepatitis c virus |
| AU2001272923A1 (en) * | 2000-05-26 | 2001-12-11 | Idenix (Cayman) Limited | Methods and compositions for treating flaviviruses and pestiviruses |
| US20030008841A1 (en) | 2000-08-30 | 2003-01-09 | Rene Devos | Anti-HCV nucleoside derivatives |
| EP1411954B1 (en) | 2000-10-18 | 2010-12-15 | Pharmasset, Inc. | Modified nucleosides for treatment of viral infections and abnormal cellular proliferation |
| JP2004532184A (ja) | 2001-01-22 | 2004-10-21 | メルク エンド カムパニー インコーポレーテッド | Ｒｎａ依存性ｒｎａウィルスポリメラーゼ阻害薬としてのヌクレオシド誘導体 |
| EP1438054A4 (en) | 2001-09-28 | 2006-07-26 | Idenix Cayman Ltd | METHODS AND COMPOSITIONS FOR TREATING FLAVIVIRUS AND PESTIVIRUS USING MODIFIED NUCLEOSIDE AT 4 'POSITION |
| AT410792B (de) | 2001-12-28 | 2003-07-25 | Dsm Fine Chem Austria Gmbh | Verfahren zur herstellung von geschützten, enantiomeren-angereicherten cyanhydrinen durch in-situ-derivatisierung |
| AU2003217863B9 (en) | 2002-02-28 | 2009-10-29 | Biota Scientific Management Pty Ltd | Nucleotide mimics and their prodrugs |
| JP2005524662A (ja) | 2002-02-28 | 2005-08-18 | ビオタ インコーポレーティッド | ヌクレオシド５’−一リン酸模倣物およびこれらのプロドラッグ |
| US20040138170A1 (en) | 2002-03-06 | 2004-07-15 | Montgomery John A. | Nucleosides, preparation thereof and use as inhibitors of rna viral polymerases |
| GB0210124D0 (en) | 2002-05-02 | 2002-06-12 | Merck Sharp & Dohme | Therapeutic agents |
| GB0210127D0 (en) | 2002-05-02 | 2002-06-12 | Merck Sharp & Dohme | Therapeutic agents |
| CA2484921A1 (en) | 2002-05-06 | 2003-11-13 | Genelabs Technologies, Inc. | Nucleoside derivatives for treating hepatitis c virus infection |
| US20050250728A1 (en) | 2002-05-23 | 2005-11-10 | Shanta Bantia | Enhancing the efficacy of reverse transcriptase and dna polymerase inhibitors (nucleoside analogs) using pnp inhibitors and/or 2'-deoxyguanosine and/or prodrug thereof |
| CN1849142A (zh) | 2002-11-15 | 2006-10-18 | 埃迪尼克斯(开曼)有限公司 | 2′－支链核苷和黄病毒突变 |
| JP5069463B2 (ja) | 2003-04-25 | 2012-11-07 | ギリアード サイエンシーズ， インコーポレイテッド | 抗ウイルス性ホスホネート類似物 |
| WO2005020885A2 (en) * | 2003-05-21 | 2005-03-10 | Isis Pharmaceuticals, Inc. | Compositions and methods for the treatment of severe acute respiratory syndrome (sars) |
| KR20060084845A (ko) * | 2003-07-25 | 2006-07-25 | 이데닉스 (케이만) 리미티드 | Ｃ형 간염을 포함하는 플라비비리다에를 치료하기 위한퓨린 뉴클레오시드 유사체 |
| KR20060123707A (ko) | 2003-08-27 | 2006-12-04 | 바이오타, 인코포레이티드 | 치료제로서의 신규 트리시클릭 뉴클레오시드 또는뉴클레오티드 |
| US7534767B2 (en) * | 2004-06-15 | 2009-05-19 | Merck & Co., Inc. | C-purine nucleoside analogs as inhibitors of RNA-dependent RNA viral polymerase |
| WO2006002231A1 (en) | 2004-06-22 | 2006-01-05 | Biocryst Pharmaceuticals, Inc. | Aza nucleosides, preparation thereof and use as inhibitors of rna viral polymerases |
| EP3109244B1 (en) | 2004-09-14 | 2019-03-06 | Gilead Pharmasset LLC | Preparation of 2'fluoro-2'-alkyl-substituted or other optionally substituted ribofuranosyl pyrimidines and purines and their derivatives |
| CN101043893A (zh) | 2004-10-21 | 2007-09-26 | 默克公司 | 治疗RNA－依赖性RNA病毒感染的氟化吡咯并[2,3－d]嘧啶核苷 |
| WO2006065335A2 (en) | 2004-10-21 | 2006-06-22 | Merck & Co., Inc. | Fluorinated pyrrolo[2,3-d]pyrimidine nucleosides for the treatment of rna-dependent rna viral infection |
| EP1814561A4 (en) | 2004-10-29 | 2012-12-19 | Biocryst Pharm Inc | THEROPUTICAL FUROPYRIMIDINES AND THIENOPYRIMIDINES |
| CA2600886A1 (en) | 2005-03-08 | 2006-09-14 | Biota Scientific Management Pty Ltd. | Bicyclic nucleosides and nucleotides as therapeutic agents |
| WO2006104945A2 (en) | 2005-03-29 | 2006-10-05 | Biocryst Pharmaceuticals, Inc. | Hepatitis c therapies |
| WO2006121820A1 (en) | 2005-05-05 | 2006-11-16 | Valeant Research & Development | Phosphoramidate prodrugs for treatment of viral infection |
| WO2007027248A2 (en) | 2005-05-16 | 2007-03-08 | Valeant Research & Development | 3', 5' - cyclic nucleoside analogues for treatment of hcv |
| US20100087388A1 (en) | 2005-10-03 | 2010-04-08 | Kotra Lakshmi P | Odcase inhibitors as anti-virals and antibiotics |
| WO2007056170A2 (en) | 2005-11-02 | 2007-05-18 | Bayer Healthcare Ag | Pyrrolo[2,1-f] [1,2,4] triazin-4-ylamines igf-1r kinase inhibitors for the treatment of cancer and other hyperproliferative diseases |
| PE20070855A1 (es) | 2005-12-02 | 2007-10-14 | Bayer Pharmaceuticals Corp | Derivados de 4-amino-pirrolotriazina sustituida como inhibidores de quinasas |
| BRPI0619146A2 (pt) | 2005-12-02 | 2011-09-13 | Bayer Pharmaceuticals Corp | derivados de 4-amino-pirroltriazina substituìda úteis no tratamento de disordens e doenças hiperproliferativas associadas com angiogênesis |
| WO2007097991A2 (en) | 2006-02-16 | 2007-08-30 | Pharmasset, Inc. | Methods and kits for dosing of antiviral agents |
| CL2007001427A1 (es) | 2006-05-22 | 2008-05-16 | Novartis Ag | Sal de maleato de 5-amino-3-(2',3'-di-o-acetil-beta-d-ribofuranosil)-3h-tiazolo[4,5-d]pirimidin-2-ona; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de una infeccion po |
| US7842672B2 (en) | 2006-07-07 | 2010-11-30 | Gilead Sciences, Inc. | Phosphonate inhibitors of HCV |
| US20080161324A1 (en) | 2006-09-14 | 2008-07-03 | Johansen Lisa M | Compositions and methods for treatment of viral diseases |
| ITBO20060683A1 (it) | 2006-10-03 | 2008-04-04 | Sympak Corazza S P A | Dispositivo per il raggruppamento di confezioni. |
| JP2010513484A (ja) | 2006-12-20 | 2010-04-30 | メルク・シャープ・エンド・ドーム・コーポレイション | Ｒｎａ依存性ｒｎａウイルス感染治療用ヌクレオシド環状ホスホロアミデート |
| US20080261913A1 (en) | 2006-12-28 | 2008-10-23 | Idenix Pharmaceuticals, Inc. | Compounds and pharmaceutical compositions for the treatment of liver disorders |
| CA2673649A1 (en) | 2007-01-05 | 2008-07-17 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | Nucleoside aryl phosphoramidates for the treatment of rna-dependent rna viral infection |
| EP2114980B1 (en) * | 2007-01-12 | 2012-06-27 | BioCryst Pharmaceuticals, Inc. | Antiviral nucleoside analogs |
| CN101730699A (zh) | 2007-03-21 | 2010-06-09 | 百时美施贵宝公司 | 可用于治疗增殖性、变应性、自身免疫性和炎症性疾病的稠合杂环化合物 |
| US7964580B2 (en) | 2007-03-30 | 2011-06-21 | Pharmasset, Inc. | Nucleoside phosphoramidate prodrugs |
| EP2155758B1 (en) * | 2007-05-10 | 2012-08-22 | Biocryst Pharmaceuticals, Inc. | Tetrahydrofuro[3,4-d]dioxolane compounds for use in the treatment of viral infections and cancer |
| CN100532388C (zh) | 2007-07-16 | 2009-08-26 | 郑州大学 | 2’-氟-4’-取代-核苷类似物、其制备方法及应用 |
| TW200942243A (en) | 2008-03-05 | 2009-10-16 | Biocryst Pharm Inc | Antiviral therapeutic agents |
| CN102046626A (zh) | 2008-04-23 | 2011-05-04 | 吉里德科学公司 | 用于抗病毒治疗的carba-核苷类似物 |
| US7863291B2 (en) | 2008-04-23 | 2011-01-04 | Bristol-Myers Squibb Company | Quinuclidine compounds as alpha-7 nicotinic acetylcholine receptor ligands |
| WO2010036407A2 (en) | 2008-05-15 | 2010-04-01 | Biocryst Pharmaceuticals, Inc. | Antiviral nucleoside analogs |
| EP2313102A2 (en) | 2008-07-03 | 2011-04-27 | Biota Scientific Management | Bycyclic nucleosides and nucleotides as therapeutic agents |
| AU2010213873B2 (en) | 2009-02-10 | 2015-07-09 | Gilead Sciences, Inc. | Carba-nucleoside analogs for antiviral treatment |
| ES2519568T3 (es) | 2009-03-24 | 2014-11-07 | Biocryst Pharmaceuticals, Inc. | Sales farmacéuticas útiles de 7-[(3R,4R)-3-hidroxi-4-hidroximetil-pirrolidin-1-ilmetil]-3,5-dihidro-pirrolo[3,2-d]pirimidin-4-ona |
| TWI583692B (zh) | 2009-05-20 | 2017-05-21 | 基利法瑪席特有限責任公司 | 核苷磷醯胺 |
| DK2480559T3 (da) | 2009-09-21 | 2013-08-05 | Gilead Sciences Inc | Fremgangsmåder og mellemprodukter til fremstillingen af 1'-cyano-carbanukleosid-analoger |
| US7973013B2 (en) | 2009-09-21 | 2011-07-05 | Gilead Sciences, Inc. | 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment |
| US8455451B2 (en) | 2009-09-21 | 2013-06-04 | Gilead Sciences, Inc. | 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment |
| KR20180006499A (ko) | 2009-09-21 | 2018-01-17 | 길리애드 사이언시즈, 인코포레이티드 | 항바이러스 치료용 ２'―플루오로 치환된 카바-뉴클레오사이드 유사체 |
| JP5872539B2 (ja) | 2010-03-31 | 2016-03-01 | ギリアド ファーマセット エルエルシー | プリンヌクレオシドホスホルアミダート |
| TW201201815A (en) | 2010-05-28 | 2012-01-16 | Gilead Sciences Inc | 1'-substituted-carba-nucleoside prodrugs for antiviral treatment |
| PH12013500033A1 (en) | 2010-07-19 | 2017-07-26 | Gilead Sciences Inc | Methods for the preparation of diasteromerically pure phosphoramidate prodrugs |
| MA34470B1 (fr) | 2010-07-22 | 2013-08-01 | Gilead Sciences Inc | Procédés et composés pour traiter des infections à virus paramyxoviridae |
| TW201305185A (zh) | 2010-09-13 | 2013-02-01 | Gilead Sciences Inc | 用於抗病毒治療之２’－氟取代之碳－核苷類似物 |
| AU2011306066B2 (en) | 2010-09-20 | 2015-01-29 | Gilead Sciences, Inc. | 2' -fluoro substituted carba-nucleoside analogs for antiviral treatment |
| BR112013009029B1 (pt) | 2010-10-15 | 2021-06-29 | Biocryst Pharmaceuticals, Inc. | Métodos e composições para inibição de polimerase |
-
2009
- 2009-04-22 CN CN2009801202188A patent/CN102046626A/zh active Pending
- 2009-04-22 AU AU2009240630A patent/AU2009240630B2/en active Active
- 2009-04-22 NZ NZ588400A patent/NZ588400A/xx unknown
- 2009-04-22 SI SI200930503T patent/SI2280973T1/sl unknown
- 2009-04-22 ES ES09734175.4T patent/ES2536193T3/es active Active
- 2009-04-22 DK DK15155479.7T patent/DK2937350T3/en active
- 2009-04-22 TW TW102115415A patent/TW201334784A/zh unknown
- 2009-04-22 BR BRPI0910455A patent/BRPI0910455B8/pt active IP Right Grant
- 2009-04-22 EP EP15155479.7A patent/EP2937350B9/en active Active
- 2009-04-22 US US12/428,234 patent/US8012941B2/en active Active
- 2009-04-22 PT PT97341754T patent/PT2268642E/pt unknown
- 2009-04-22 CN CN201410408008.1A patent/CN104262345B/zh active Active
- 2009-04-22 BR BRPI0911410A patent/BRPI0911410A2/pt not_active Application Discontinuation
- 2009-04-22 WO PCT/US2009/041447 patent/WO2009132135A1/en not_active Ceased
- 2009-04-22 PT PT151554797T patent/PT2937350T/pt unknown
- 2009-04-22 SI SI200931823T patent/SI2937350T1/en unknown
- 2009-04-22 KR KR1020107026265A patent/KR101645742B1/ko active Active
- 2009-04-22 ME MEP-2018-95A patent/ME03089B/me unknown
- 2009-04-22 TW TW098113324A patent/TWI401084B/zh active
- 2009-04-22 PT PT97351621T patent/PT2280973E/pt unknown
- 2009-04-22 MX MX2010011659A patent/MX2010011659A/es active IP Right Grant
- 2009-04-22 PL PL09735162T patent/PL2280973T3/pl unknown
- 2009-04-22 US US12/428,176 patent/US8008264B2/en active Active
- 2009-04-22 CN CN200980114224.2A patent/CN102015714B/zh active Active
- 2009-04-22 KR KR1020107026178A patent/KR101681559B1/ko active Active
- 2009-04-22 PL PL09734175T patent/PL2268642T3/pl unknown
- 2009-04-22 EA EA201071128A patent/EA019883B1/ru not_active IP Right Cessation
- 2009-04-22 MX MX2010011661A patent/MX2010011661A/es active IP Right Grant
- 2009-04-22 NZ NZ588670A patent/NZ588670A/xx not_active IP Right Cessation
- 2009-04-22 DK DK09734175.4T patent/DK2268642T3/en active
- 2009-04-22 AR ARP090101420A patent/AR071395A1/es active IP Right Grant
- 2009-04-22 RS RS20150348A patent/RS54008B1/sr unknown
- 2009-04-22 AU AU2009240642A patent/AU2009240642B2/en active Active
- 2009-04-22 AP AP2010005414A patent/AP3237A/xx active
- 2009-04-22 CA CA2722084A patent/CA2722084C/en active Active
- 2009-04-22 SI SI200931153T patent/SI2268642T1/sl unknown
- 2009-04-22 PL PL15155479T patent/PL2937350T3/pl unknown
- 2009-04-22 LT LTEP15155479.7T patent/LT2937350T/lt unknown
- 2009-04-22 RS RS20180408A patent/RS57092B1/sr unknown
- 2009-04-22 EP EP09734175.4A patent/EP2268642B1/en active Active
- 2009-04-22 JP JP2011506429A patent/JP5425186B2/ja active Active
- 2009-04-22 DK DK09735162.1T patent/DK2280973T3/da active
- 2009-04-22 KR KR1020167033059A patent/KR101856404B1/ko active Active
- 2009-04-22 HU HUE15155479A patent/HUE038946T2/hu unknown
- 2009-04-22 HR HRP20130048AT patent/HRP20130048T1/hr unknown
- 2009-04-22 HR HRP20150359TT patent/HRP20150359T1/hr unknown
- 2009-04-22 JP JP2011506435A patent/JP5425187B2/ja active Active
- 2009-04-22 HU HUE09734175A patent/HUE025528T2/en unknown
- 2009-04-22 ES ES09735162T patent/ES2398684T3/es active Active
- 2009-04-22 ES ES15155479.7T patent/ES2665272T3/es active Active
- 2009-04-22 CA CA2722177A patent/CA2722177C/en active Active
- 2009-04-22 NO NO15155479A patent/NO2937350T3/no unknown
- 2009-04-22 AP AP2010005439A patent/AP3076A/xx active
- 2009-04-22 EP EP09735162A patent/EP2280973B1/en active Active
- 2009-04-22 WO PCT/US2009/041432 patent/WO2009132123A1/en not_active Ceased
- 2009-04-22 EA EA201071170A patent/EA020659B1/ru unknown
-
2010
- 2010-09-30 CO CO10121513A patent/CO6321235A2/es not_active Application Discontinuation
- 2010-10-06 IL IL208515A patent/IL208515A/en active IP Right Grant
- 2010-10-14 IL IL208701A patent/IL208701A/en active IP Right Grant
- 2010-10-22 CO CO10131479A patent/CO6300958A2/es not_active Application Discontinuation
- 2010-10-28 ZA ZA2010/07713A patent/ZA201007713B/en unknown
- 2010-11-09 ZA ZA2010/08008A patent/ZA201008008B/en unknown
- 2010-11-15 EC EC2010010609A patent/ECSP10010609A/es unknown
- 2010-11-19 EC EC2010010618A patent/ECSP10010618A/es unknown
-
2011
- 2011-08-02 US US13/196,117 patent/US8318682B2/en active Active
-
2012
- 2012-10-11 US US13/649,511 patent/US8853171B2/en not_active Ceased
-
2013
- 2013-02-08 CY CY20131100119T patent/CY1113647T1/el unknown
- 2013-10-21 JP JP2013218129A patent/JP2014040471A/ja not_active Withdrawn
- 2013-10-21 JP JP2013218139A patent/JP2014012739A/ja not_active Withdrawn
-
2015
- 2015-05-11 CY CY20151100412T patent/CY1116425T1/el unknown
-
2016
- 2016-10-07 US US15/288,271 patent/USRE46762E1/en active Active
-
2018
- 2018-04-04 CY CY20181100377T patent/CY1120366T1/el unknown
- 2018-04-10 HR HRP20180572TT patent/HRP20180572T1/hr unknown
-
2020
- 2020-12-17 LU LU00193C patent/LUC00193I2/en unknown
- 2020-12-18 CY CY2020044C patent/CY2020044I2/el unknown
- 2020-12-18 LT LTPA2020539C patent/LTC2937350I2/lt unknown
- 2020-12-18 HU HUS2000055C patent/HUS2000055I1/hu unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011521903A5 (enExample) | ||
| JP2011518835A5 (enExample) | ||
| JP2012517444A5 (enExample) | ||
| JP2014514308A5 (enExample) | ||
| JP2010539241A5 (enExample) | ||
| JP2013538230A5 (enExample) | ||
| JP2012519691A5 (enExample) | ||
| JP2014503516A5 (enExample) | ||
| HRP20150359T1 (hr) | 1'-supstituirani karba-nukleozidni analozi za antivirusnu terapiju | |
| ME01882B (me) | 1 '-supstituisani-karba-nukleozidni prolekovi za antivirusni tretman | |
| JP2016503800A5 (enExample) | ||
| JP2010515760A5 (enExample) | ||
| JP2014504643A5 (enExample) | ||
| CA2490200A1 (en) | 2' and 3'-nucleoside prodrugs for treating flaviviridae infections | |
| JP2011520906A5 (enExample) | ||
| JP2010518047A5 (enExample) | ||
| JP2005524632A5 (enExample) | ||
| JP2015525220A5 (enExample) | ||
| JP2012504126A5 (enExample) | ||
| RU2012117395A (ru) | Новые макроциклические ингибиторы репликации вируса гепатита с | |
| CN1482914A (zh) | 丙型肝炎治疗剂 | |
| JP2015512860A5 (enExample) | ||
| JP2011521911A5 (enExample) | ||
| JP2011511841A5 (enExample) | ||
| JP2013523765A5 (enExample) |